The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Current and experimental treatments of Parkinson disease: A guide for neuroscientists
Open accessAbstract
Over a period of more than 50 years, the symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been optimized using pharmacotherapy, deep brain stimulation, and physiotherapy. The arsenal of pharmacotherapies includes L‐Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)‐B and catechol‐o‐methyltransferase (COMT), and amantadine. In the later course of the disease, motor complications occur, at which stage different oral formulations of L‐Dopa or dopamine agonists with long half‐life, a transdermal application or parenteral pumps for continuous drug supply can be subscribed. Alternatively, the patient is offered deep brain stimulation of the subthalamic nucleus (STN) or the internal part of the globus pallidus (GP i). For a more efficacious treatment of motor complications, new formulations of L‐Dopa, dopamine agonists, and amantadine as well as new MAO‐B and COMT inhibitors are currently tested in clinical trials, and some of them already yielding positive results in phase 3 trials. In addition, non‐dopaminergic agents have been tested in the early clinical phase for the treatment of motor fluctuations and dyskinesia, including adenosine A2A antagonists (istradefylline, preladenant, and tozadenant) and modulators of the metabolic glutamate receptor 5 (mG luR5 ‐ mavoglurant) and serotonin (eltoprazine) receptors. Recent clinical trials testing coenzyme Q10, the dopamine agonist pramipexole, creatine monohydrate, pioglitazone, or AAV‐mediated gene therapy aimed at increasing expression of neurturin, did not prove efficacious. Treatment with nicotine, caffeine, inosine (a precursor of urate), and isradipine (a dihydropyridine calcium channel blocker), as well as active and passive immunization against α‐synuclein and inhibitors or modulators of α‐synuclein‐aggregation are currently studied in clinical trials. However, to date, no disease‐modifying treatment is available. We here review the current status of treatment options for motor and non‐motor symptoms, and discuss current investigative strategies for disease modification. This review provides basic insights, mainly addressing basic scientists and non‐specialists. It stresses the need to intensify therapeutic PD research and points out reasons why the translation of basic research to disease‐modifying therapies has been unsuccessful so far. image The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L‐Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)‐B and catechol‐o‐methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy. For a more efficacious treatment of motor complications, new formulations of L‐Dopa, dopamine agonists, and amantadine as well as new MAO‐B and COMT inhibitors are currently tested in clinical trials. Non‐dopaminergic agents have been tested in the early clinical phase for the treatment of motor fluctuations and dyskinesia. Recent clinical trials testing coenzyme Q10, the dopamine agonist pramipexole, creatine monohydrate, pioglitazone, or AAV‐mediated gene therapy aimed at increasing expression of neurturin, did not prove efficacious. Treatment with nicotine, caffeine, and isradipine – a dihydropyridine calcium channel blocker – as well as active and passive immunization against α‐synuclein and inhibitors of α‐synuclein‐aggregation are currently studied in clinical trials. However, to date, no disease‐modifying treatment is available for PD. We here review the current status of treatment options and investigative strategies for both motor and non‐motor symptoms. This review stresses the need to intensify therapeutic PD research and points out reasons why the translation of basic research to disease‐modifying therapies has been unsuccessful so far. This article is part of a special issue on Parkinson disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
Self-citationLevodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
MDS research criteria for prodromal Parkinson's disease
Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G., Joseph, L., et al. (2015) · Movement Disorders · doi:10.1002/mds.26431 · Cited by 1,309
Self-citationGoedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Luk, K. C., Kehm, V. M., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M. Y. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112457 · Cited by 1,100
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
Cited by
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Cacabelos, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030551 · Cited by 555
Glutamate-induced excitotoxicity in Parkinson's disease: The role of glial cells
Iovino, L., Tremblay, M. E., & Civiero, L. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.07.011 · Cited by 374
C-terminal calcium binding of α-synuclein modulates synaptic vesicle interaction
Lautenschläger, J., Stephens, A. D., Fusco, G., Ströhl, F., Curry, N., Zacharopoulou, M., Michel, C. H., Laine, R., Nespovitaya, N., Fantham, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03111-4 · Cited by 334
Monzani, E., Nicolis, S., Dell'Acqua, S., Capucciati, A., Bacchella, C., Zucca, F. A., Mosharov, E. V., Sulzer, D., Zecca, L., & Casella, L. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201811122 · Cited by 271
Kjaergaard, J., Hatfield, S., Jones, G., Ohta, A., & Sitkovsky, M. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700850 · Cited by 132
Rosa, A. I., Fonseca, I., Nunes, M. J., Moreira, S., Rodrigues, E., Carvalho, A. N., Rodrigues, C. M. P., Gama, M. J., & Castro-Caldas, M. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.06.004 · Cited by 82
Potential Treatment of Parkinson’s Disease with Omega-3 Polyunsaturated Fatty Acids
Li, P., & Song, C. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1735143 · Cited by 74
Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · doi:10.20944/preprints202506.2099.v2 · Cited by 57
Khan, A. F., Adewale, Q., Lin, S.-J., Baumeister, T. R., Zeighami, Y., Carbonell, F., Palomero-Gallagher, N., & Iturria-Medina, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-41677-w · Cited by 28
Metadata
- Authors
- Oertel, W., & Schulz, J. B.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2016-08-30
- Volume
- 139
- Issue
- S1
- Pages
- 325-337
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2516348886
- Cited by
- 369
- References
- 80
- FWCI
- 27.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.